Home/Filings/4/0001140361-17-029089
4//SEC Filing

Richard Stark 4

Accession 0001140361-17-029089

CIK 0001275187other

Filed

Jul 27, 8:00 PM ET

Accepted

Jul 28, 3:15 PM ET

Size

13.2 KB

Accession

0001140361-17-029089

Insider Transaction Report

Form 4
Period: 2017-07-22
Richard Stark
SVP, GM - Oncology
Transactions
  • Tax Payment

    Common Stock

    2017-07-25$17.12/sh432$7,39617,608 total
  • Tax Payment

    Common Stock

    2017-07-22$16.80/sh393$6,60218,040 total
  • Award

    Performance Right

    2017-07-26+7,2967,296 total
    Common Stock (7,296 underlying)
  • Award

    Common Stock

    2017-07-26+3,64821,256 total
  • Award

    Non-Qualified Stock Option (right to buy)

    2017-07-26+12,81812,818 total
    Exercise: $16.55From: 2018-07-26Exp: 2027-07-26Common Stock (12,818 underlying)
Footnotes (5)
  • [F1]The exempt disposition of 393 shares of common stock ("Common Stock") of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 22, 2015.
  • [F2]The exempt disposition of 432 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 25, 2014.
  • [F3]This acquisition of 3,648 shares of Common Stock represents 3,648 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 26, 2018, such that 25% of the restricted stock units will vest on each of July 26, 2018, 2019, 2020 and 2021.
  • [F4]These stock options vest in four equal annual installments beginning on July 26, 2018, such that 25% of the options will vest on each of July 26, 2018, 2019, 2020 and 2021.
  • [F5]Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited.

Documents

1 file

Issuer

ANGIODYNAMICS INC

CIK 0001275187

Entity typeother

Related Parties

1
  • filerCIK 0001539142

Filing Metadata

Form type
4
Filed
Jul 27, 8:00 PM ET
Accepted
Jul 28, 3:15 PM ET
Size
13.2 KB